You are here
- Home
- Drug Products
- All Drug Products
A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
- Disease
- non-small cell lung cancer
- Drug Name
- AstraZeneca Oncology and Infection Development Drugs
- Generic Name
- AZD6244
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- I
- Start Date
- Jan 18, 1971
- Study Name
- D1532C00067
- Study Id
- D1532C00067
- ClinicalTrials.gov ID
- NCT01605916
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
